Brooke Shields Breaks Femur, Shares Video Trying to Walk on Crutches prevention.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prevention.com Daily Mail and Mail on Sunday newspapers.
Workers near Derbyshire toxic waste dump seen without masks or gloves derbytelegraph.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from derbytelegraph.co.uk Daily Mail and Mail on Sunday newspapers.
(3)
Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation
Agreement aims to address disparity in access to treatments and to prioritize populations and regions that bear the
greatest burden of sickle cell disease in the search for curative therapies
Effort expands on Novartis commitment to sickle cell disease, which includes a therapeutic pipeline and a holistic approach to diagnosis, treatment, and management of the disease in sub-Saharan Africa
Basel, February 17, 2021 - Novartis today announced that it has entered into a grant agreement with the Bill & Melinda Gates Foundation. As part of the agreement, the foundation will provide funding support for the discovery and development of a single-administration,
BASEL, SWITZERLAND,
February 17, 2021 /3BL Media/ Novartis today announced that it has entered into a grant agreement with the Bill & Melinda Gates Foundation. As part of the agreement, the foundation will provide funding support for the discovery and development of a single-administration,
in vivo gene therapy to cure sickle cell disease (SCD). The project brings together Novartis drug discovery and gene therapy expertise with the Gates Foundation’s charitable objectives to expand access to healthcare in low-resource settings in an effort to address this potentially life-threatening genetic disease.
“Existing gene therapy approaches to sickle cell disease are difficult to deliver at scale and there are obstacles to reaching the vast majority of those affected by this debilitating disease,” said Jay Bradner, a hematologist and President of the Novartis Institutes for BioMedical Research (NIBR). “This is a challenge that calls for collective action, and we are thrill